Browse Studies — Arctuva

Phase 2

A Randomized, Double-Blind, Placebo-Controlled, Delayed-Start Study to Evaluate the Efficacy and Safety of Exaluren in Alport Syndrome Patients With Nonsense Mutations in COL4A3/4/5 Genes

This is a randomized, double-Blind, placebo-controlled study to evaluate the efficacy and safety of exaluren in Alport Syndrome patients with nonsense mutation…

Alport Syndrome, X-LinkedAlport Syndrome, Autosomal Recessive

Estimated

~$10 – $8,750

Eloxx Pharmaceuticals, Inc.NCT07523581

Phase 2

A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108…

Focal Segmental GlomerulosclerosisMinimal Change DiseaseImmunoglobulin A Nephropathy+2 more

Estimated

~$10 – $8,750

Travere Therapeutics, Inc.NCT05003986

Observational

Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)

NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial match…

Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change Disease+6 more

Estimated

~$10 – $6,250

University of MichiganNCT04571658

Alport Syndrome Foundation Alport Patient Registry

Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US…

Alport SyndromeThin Basement Membrane DiseaseHereditary Nephritis

Estimated

~$10 – $750

Alport Syndrome FoundationNCT06526741